Results 131 to 140 of about 93,898 (384)

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

European Respiratory Journal, 2020
Background Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation.
C. Taillé, P. Chanez, G. Devouassoux, A. Didier, C. Pison, G. Garcia, J. Charriot, S. Bouée, A. Gruber, C. Pribil, A. Bourdin, M. Humbert   +11 more
semanticscholar   +1 more source

Clinical usefulness of mepolizumab in severe eosinophilic asthma

Therapeutics and Clinical Risk Management, 2016
Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis
Menzella, Francesco, Lusuardi,Mirco, Montanari,Gloria, Galeone,Carla, Facciolongo,Nicola, Zucchi,Luigi   +5 more
openaire   +5 more sources

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

What's new in the diagnosis and management of food allergy in children? [PDF]

, 2013
This article reviews the recent advances in the diagnosis and management of IgE mediated food allergy in children. It will encompass the emerging technology of component testing; moves to standardization of the allergy food challenge; permissive diets ...
Campbell, DE, Turner, PJ
core   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Journal of Medical Case Reports
Background The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5/interleukin ...
M. Sabbe, F. Schleich, P. Janssens, R. Louis   +3 more
doaj   +1 more source

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports [PDF]

, 2021
Laura Pini, Cristiano Caruso, Stefania Colantuono, Diego Bagnasco, Aoife C. Maxwell, Robert G. Price, Peter Howarth, Giorgio Walter Canonica, Italian investigators of REALITI‐A   +8 more
openalex   +1 more source

Noninvasive Disease Diagnostics: The Swiss Contribution Highlights to Breath Analysis Research

Helvetica Chimica Acta, EarlyView.
Breath analysis networks across Switzerland linking health monitoring, clinical applications, population studies, and data‐driven public health decisions. ABSTRACT To celebrate the 125th anniversary of the Swiss Chemical Society, we present a review and perspective to highlight the recent research in breath analysis that has been conducted in ...
Stefan James Swift, Kseniya Dryahina, Patrik Španěl, Flora Kontopidou, Christos Kokkotis, Renato Zenobi, Stamatios Giannoukos   +6 more
wiley   +1 more source

Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. [PDF]

, 2013
Nanocarriers can deliver a wide variety of drugs, target them to sites of interest, and protect them from degradation and inactivation by the body. They have the capacity to improve drug action and decrease undesirable systemic effects.
Bratt, Jennifer M, Franzi, Lisa M, Kenyon, Nicholas J, Lam, Kit S, Lee, Joyce, Luo, Juntao, Zeki, Amir A   +6 more
core   +2 more sources

Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Nonesophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) are rare, underrecognized inflammatory diseases of the gastrointestinal (GI) tract, especially in children. Their clinical heterogeneity and lack of specific biomarkers contribute to diagnostic delays and therapeutic challenges.
Sara Renzo, Luca Scarallo, Selene Del Vespa, Giulia Angelino, Matteo Bramuzzo, Enrico Felici, Flavio Labriola, Francesca Laganà, Lorenzo Norsa, Salvatore Oliva, Marisa Piccirillo, Elena Pozzi, Francesca Rea, Giusy Russo, Francesco Valitutti, Giovanna Zuin, Paolo Lionetti   +16 more
wiley   +1 more source